Global Injectable Drug Delivery Market - Trends and Forecast to 2024
Synopsis:
Global Injectable Drug Delivery Market is expected to reach USD 789.7 billion by 2024, at a CAGR 11.5% during the forecast period of 2017 to 2024. The report contains 871 pages of exclusive premium insights with 954 tables and 50 figures.
The global injectable drug delivery market has been segmented On the basis of product type into devices and formulations.
Based on application the market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.
On the basis of usage patter the market is segmented into curative care, immunization, and others.
Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.
Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.
Major Players Operating in this market:
Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, and Teva Pharmaceuticals Industries Ltd. among others
Regions Covered In The Scope Of The Report:
Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa (South Africa, Rest of MEA))
Global Injectable Drug Delivery Market is expected to reach USD 789.7 billion by 2024, at a CAGR 11.5% during the forecast period of 2017 to 2024. The report contains 871 pages of exclusive premium insights with 954 tables and 50 figures.
The global injectable drug delivery market has been segmented On the basis of product type into devices and formulations.
Based on application the market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.
On the basis of usage patter the market is segmented into curative care, immunization, and others.
Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.
Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.
Major Players Operating in this market:
Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, and Teva Pharmaceuticals Industries Ltd. among others
Regions Covered In The Scope Of The Report:
Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa (South Africa, Rest of MEA))
1 INTRODUCTION
1.1. OVERVIEW OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.4. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.5. ASSUMPTIONS
3 MARKET LANDSCAPE SUMMARY
4 PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5 INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.2.1. INJECTABLE DRUG DELIVERY DEVICES
5.2.2. INJECTABLE DRUG DELIVERY FORMULATIONS
6 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
61. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.2.1. BY MATERIAL
6.2.1.1. GLASS
6.2.1.2. PLASTIC
6.2.2. BY PRODUCT
6.2.2.1. EMPTY SYRINGES
6.2.2.2. PREFILLED SYRINGES
6.2.3. BY USABILITY
6.2.3.1. REUSABLE SYRINGES
6.2.3.2. DISPOSABLE SYRINGES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTORS
6.3.1.1. BY PRODUCT
6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
6.3.1.2. 2. PREFILLED NEEDLE FREE INJECTORS
6.3.1.2. BY TECHNOLOGY
6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
6.3.1.3. BY USABILITY
6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
6.3.2. AUTO INJECTORS
6.3.2.1. BY PRODUCT
6.3.2.1.1. EMPTY AUTO INJECTORS
6.3.2.2. 2. PREFILLED AUTO INJECTORS
6.3.2.2. BY TECHNOLOGY
6.3.2.2.1. AUTOMATED AUTO INJECTORS
6.3.2.2.2. MANUAL AUTO INJECTORS
6.3.2.3. BY DESIGN
6.3.2.3.1. STANDARDIZED AUTO INJECTORS
6.3.2.3.2. CUSTOMIZED AUTO INJECTORS
6.3.2.4. BY USABILITY
6.3.2.4.1. REUSABLE AUTO INJECTORS
6.3.2.4.2. DISPOSABLE AUTO INJECTORS
6.3.3. PEN INJECTORS
6.3.3.1. BY PRODUCT
6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
6.3.3.2. 2. DUAL CHAMBERED PEN INJECTORS
6.3.3.2. BY DESIGN
6.3.3.2.1. STANDARDIZED PEN INJECTORS
6.3.3.2.2. CUSTOMIZED PEN INJECTORS
6.3.3.3. BY USABILITY
6.3.3.3.1. REUSABLE PEN INJECTORS
6.3.3.3.2. DISPOSABLE PEN INJECTORS
6.3.4. WEARABLE INJECTORS
6.3.5. OTHER INJECTABLE DEVICES
7. INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.2.1. SOLUTIONS
7.2.3. RECONSTITUED/LYOPHILIZED FORMULATIONS
7.2.3. SUSPENSIONS
7.2.3. EMULSIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
7.2.1. COLLOIDAL DISPERSIONS
7.2.1.1. LIPOSOMES
7.2.1.2. NIOSOMES
7.2.1.3. POLYMERIC MIXED
7.2.1.4. NANOPARTICLES
7.2.1.4.1. NANOSUSPENSIONS
7.2.1.4.2. NANOEMULSIONS/MICROEMULSIONS
7.2.1.4.3. SOLID LIPID NANOPARTICLES
7.2.2. MICROPARTICLES
7.2.2.1. MICROSPHERES
7.2.2.2. MICROCAPSULES
7.2.3. LONG LASTING FORMULATIONS
8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.2.1. RHEUMATOID ARTHRITIS
8.2.2. MULTIPLE SCLEROSIS
8.2.3. CHRON’S DISEASE
8.2.4. PSORIASIS
8.2.5. OTHER AUTOIMMUNE DIDEASES
8.3. HORMONAL DISORDERS
8.3.1. DIABETES
8.3.2. ANEMIA
8.3.3. REPRODUCTIVE HEALTH DISEASES
8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. GROWTH HORMONE DEFICIENCY (GHD)
8.4 ORPHAN DISEASES
8.5 ONCOLOGY
8.6 OTHERS
8.6.1. PAIN MANAGEMENT
8.6.2. ALLERGY TREATMENT
8.6.3. AESTHETIC TREATMENT
8.6.4. HEPATITIS C
8.6.5. HEMOPHILIA
9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10 INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.4. CENTRAL NERVOUS SYSTEM
11 INJECTABLE DRUG DELIVERY MARKET, BY END USERS
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHERS
12 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
12.1. OVERVIEW
12.2. DIRECT TENDERS
12.3. HOSPITAL PHARMACY
12.4. PHARMACY STORES
12.5. ONLINE PHARMACY
12.6. OTHERS
13 INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
13.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
13.1.1. NORTH AMERICA
13.1.1.1. U.S.
13.1.1.2. CANADA
13.1.1.3. MEXICO
13.1.2. EUROPE
13.1.2.1. GERMANY
13.1.2.2. FRANCE
13.1.2.3. U.K.
13.1.2.4. ITALY
13.1.2.5. SPAIN
13.1.2.6. RUSSIA
13.1.2.7. TURKEY
13.1.2.8. BELGIUM
13.1.2.9. NETHERLANDS
13.1.2.10. SWITZERLAND
13.1.2.11. REST OF EUROPE
13.1.3. ASIA-PACIFIC (APAC)
13.1.3.1. JAPAN
13.1.3.2. CHINA
13.1.3.3. SOUTH KOREA
13.1.3.4. INDIA
13.1.3.5. AUSTRALIA
13.1.3.6. SINGAPORE
13.1.3.7. THAILAND
13.1.3.8. MALAYSIA
13.1.3.9. INDONESIA
13.1.3.10. PHILIPPINES
13.1.3.11. REST OF APAC
13.1.4. LATIN AMERICA
13.1.4.1. BRAZIL
13.1.4.2. REST OF LATIN AMERICA
13.1.5. MIDDLE EAST AND AFRICA
13.1.5.1. SOUTH AFRICA
13.1.5.2. REST OF MIDDLE EAST AND AFRICA
13.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
14 INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
14.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.7. MERGERS & ACQUISITIONS
14.8. NEW PRODUCT DEVELOPMENT & APPROVALS
14.9. EXPANSIONS
14.10. REGULATORY CHANGES
14.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
15 INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
15.1 BAXTER INTERNATIONAL, INC.
15.1.1 COMPANY OVERVIEW
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPEMENTS
15.1.5 DATA BRIDGE ANALYSIS
15.2 BECTON, DICKINSON AND COMPANY
15.2.1 COMPANY OVERVIEW
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPEMENTS
15.2.5 DATA BRIDGE ANALYSIS
15.3 GERRESHEIMER, AG
15.3.1 COMPANY OVERVIEW
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPEMENTS
15.3.5 DATA BRIDGE ANALYSIS
15.4 PFIZER, INC.
15.4.1 COMPANY OVERVIEW
15.4.2 REVENUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPEMENTS
15.4.5 DATA BRIDGE ANALYSIS
15.5 SCHOTT AG
15.5.1 COMPANY OVERVIEW
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPEMENTS
15.5.5 DATA BRIDGE ANALYSIS
15.6 ALKERMES PLC
15.6.1 COMPANY OVERVIEW
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPEMENTS
15.6.5 DATA BRIDGE ANALYSIS
15.7 ELI LILLY AND COMPANY
15.7.1 COMPANY OVERVIEW
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPEMENTS
15.7.5 DATA BRIDGE ANALYSIS
15.8 SANDOZ
15.8.1 COMPANY OVERVIEW
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPEMENTS
15.8.5 DATA BRIDGE ANALYSIS
15.9 TERUMO CORPORATION
15.9.1 COMPANY OVERVIEW
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPEMENTS
15.9.5 DATA BRIDGE ANALYSIS
15.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
15.10.1 COMPANY OVERVIEW
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPEMENTS
15.10.5 DATA BRIDGE ANALYSIS
16 APPENDIX
16.1. RELATED REPORTS
16.2. CUSTOMIZABLE OPTIONS
16.3. SOURCE SHEET
16.4. BIBLIOGRAPHY
17 ABOUT DATA BRIDGE MARKET RESEARCH
1.1. OVERVIEW OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.4. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.5. ASSUMPTIONS
3 MARKET LANDSCAPE SUMMARY
4 PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5 INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.2.1. INJECTABLE DRUG DELIVERY DEVICES
5.2.2. INJECTABLE DRUG DELIVERY FORMULATIONS
6 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
61. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.2.1. BY MATERIAL
6.2.1.1. GLASS
6.2.1.2. PLASTIC
6.2.2. BY PRODUCT
6.2.2.1. EMPTY SYRINGES
6.2.2.2. PREFILLED SYRINGES
6.2.3. BY USABILITY
6.2.3.1. REUSABLE SYRINGES
6.2.3.2. DISPOSABLE SYRINGES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTORS
6.3.1.1. BY PRODUCT
6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
6.3.1.2. 2. PREFILLED NEEDLE FREE INJECTORS
6.3.1.2. BY TECHNOLOGY
6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
6.3.1.3. BY USABILITY
6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
6.3.2. AUTO INJECTORS
6.3.2.1. BY PRODUCT
6.3.2.1.1. EMPTY AUTO INJECTORS
6.3.2.2. 2. PREFILLED AUTO INJECTORS
6.3.2.2. BY TECHNOLOGY
6.3.2.2.1. AUTOMATED AUTO INJECTORS
6.3.2.2.2. MANUAL AUTO INJECTORS
6.3.2.3. BY DESIGN
6.3.2.3.1. STANDARDIZED AUTO INJECTORS
6.3.2.3.2. CUSTOMIZED AUTO INJECTORS
6.3.2.4. BY USABILITY
6.3.2.4.1. REUSABLE AUTO INJECTORS
6.3.2.4.2. DISPOSABLE AUTO INJECTORS
6.3.3. PEN INJECTORS
6.3.3.1. BY PRODUCT
6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
6.3.3.2. 2. DUAL CHAMBERED PEN INJECTORS
6.3.3.2. BY DESIGN
6.3.3.2.1. STANDARDIZED PEN INJECTORS
6.3.3.2.2. CUSTOMIZED PEN INJECTORS
6.3.3.3. BY USABILITY
6.3.3.3.1. REUSABLE PEN INJECTORS
6.3.3.3.2. DISPOSABLE PEN INJECTORS
6.3.4. WEARABLE INJECTORS
6.3.5. OTHER INJECTABLE DEVICES
7. INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.2.1. SOLUTIONS
7.2.3. RECONSTITUED/LYOPHILIZED FORMULATIONS
7.2.3. SUSPENSIONS
7.2.3. EMULSIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
7.2.1. COLLOIDAL DISPERSIONS
7.2.1.1. LIPOSOMES
7.2.1.2. NIOSOMES
7.2.1.3. POLYMERIC MIXED
7.2.1.4. NANOPARTICLES
7.2.1.4.1. NANOSUSPENSIONS
7.2.1.4.2. NANOEMULSIONS/MICROEMULSIONS
7.2.1.4.3. SOLID LIPID NANOPARTICLES
7.2.2. MICROPARTICLES
7.2.2.1. MICROSPHERES
7.2.2.2. MICROCAPSULES
7.2.3. LONG LASTING FORMULATIONS
8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.2.1. RHEUMATOID ARTHRITIS
8.2.2. MULTIPLE SCLEROSIS
8.2.3. CHRON’S DISEASE
8.2.4. PSORIASIS
8.2.5. OTHER AUTOIMMUNE DIDEASES
8.3. HORMONAL DISORDERS
8.3.1. DIABETES
8.3.2. ANEMIA
8.3.3. REPRODUCTIVE HEALTH DISEASES
8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. GROWTH HORMONE DEFICIENCY (GHD)
8.4 ORPHAN DISEASES
8.5 ONCOLOGY
8.6 OTHERS
8.6.1. PAIN MANAGEMENT
8.6.2. ALLERGY TREATMENT
8.6.3. AESTHETIC TREATMENT
8.6.4. HEPATITIS C
8.6.5. HEMOPHILIA
9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10 INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.4. CENTRAL NERVOUS SYSTEM
11 INJECTABLE DRUG DELIVERY MARKET, BY END USERS
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHERS
12 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
12.1. OVERVIEW
12.2. DIRECT TENDERS
12.3. HOSPITAL PHARMACY
12.4. PHARMACY STORES
12.5. ONLINE PHARMACY
12.6. OTHERS
13 INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
13.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
13.1.1. NORTH AMERICA
13.1.1.1. U.S.
13.1.1.2. CANADA
13.1.1.3. MEXICO
13.1.2. EUROPE
13.1.2.1. GERMANY
13.1.2.2. FRANCE
13.1.2.3. U.K.
13.1.2.4. ITALY
13.1.2.5. SPAIN
13.1.2.6. RUSSIA
13.1.2.7. TURKEY
13.1.2.8. BELGIUM
13.1.2.9. NETHERLANDS
13.1.2.10. SWITZERLAND
13.1.2.11. REST OF EUROPE
13.1.3. ASIA-PACIFIC (APAC)
13.1.3.1. JAPAN
13.1.3.2. CHINA
13.1.3.3. SOUTH KOREA
13.1.3.4. INDIA
13.1.3.5. AUSTRALIA
13.1.3.6. SINGAPORE
13.1.3.7. THAILAND
13.1.3.8. MALAYSIA
13.1.3.9. INDONESIA
13.1.3.10. PHILIPPINES
13.1.3.11. REST OF APAC
13.1.4. LATIN AMERICA
13.1.4.1. BRAZIL
13.1.4.2. REST OF LATIN AMERICA
13.1.5. MIDDLE EAST AND AFRICA
13.1.5.1. SOUTH AFRICA
13.1.5.2. REST OF MIDDLE EAST AND AFRICA
13.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
14 INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
14.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
14.7. MERGERS & ACQUISITIONS
14.8. NEW PRODUCT DEVELOPMENT & APPROVALS
14.9. EXPANSIONS
14.10. REGULATORY CHANGES
14.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
15 INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
15.1 BAXTER INTERNATIONAL, INC.
15.1.1 COMPANY OVERVIEW
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPEMENTS
15.1.5 DATA BRIDGE ANALYSIS
15.2 BECTON, DICKINSON AND COMPANY
15.2.1 COMPANY OVERVIEW
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPEMENTS
15.2.5 DATA BRIDGE ANALYSIS
15.3 GERRESHEIMER, AG
15.3.1 COMPANY OVERVIEW
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPEMENTS
15.3.5 DATA BRIDGE ANALYSIS
15.4 PFIZER, INC.
15.4.1 COMPANY OVERVIEW
15.4.2 REVENUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPEMENTS
15.4.5 DATA BRIDGE ANALYSIS
15.5 SCHOTT AG
15.5.1 COMPANY OVERVIEW
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPEMENTS
15.5.5 DATA BRIDGE ANALYSIS
15.6 ALKERMES PLC
15.6.1 COMPANY OVERVIEW
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPEMENTS
15.6.5 DATA BRIDGE ANALYSIS
15.7 ELI LILLY AND COMPANY
15.7.1 COMPANY OVERVIEW
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPEMENTS
15.7.5 DATA BRIDGE ANALYSIS
15.8 SANDOZ
15.8.1 COMPANY OVERVIEW
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPEMENTS
15.8.5 DATA BRIDGE ANALYSIS
15.9 TERUMO CORPORATION
15.9.1 COMPANY OVERVIEW
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPEMENTS
15.9.5 DATA BRIDGE ANALYSIS
15.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
15.10.1 COMPANY OVERVIEW
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPEMENTS
15.10.5 DATA BRIDGE ANALYSIS
16 APPENDIX
16.1. RELATED REPORTS
16.2. CUSTOMIZABLE OPTIONS
16.3. SOURCE SHEET
16.4. BIBLIOGRAPHY
17 ABOUT DATA BRIDGE MARKET RESEARCH
